Immunomodulatory drugs: new developments

Onderzoeksoutput: Articlepeer review


The immunomodulatory drugs (IMiDs) are a class of orally available compounds which are licensed for the treatment of multiple myeloma (thalidomide, lenalidomide) and transfusion-dependent low- and intermediate-risk myelodysplasia (MDS) with deletion of long arm of chromosome 5 (lenalidomide). Pomalidomide, a novel second generation IMiD, is entering clinical trials and seems to further broaden the therapeutic spectrum of these already pleiotropic drugs. Here we summarise new insights into the mechanism of action of IMiDs as well as new developments related to their clinical use, as maintenance therapy in multiple myeloma (MM), in the treatment of myeloproliferative neoplasm- associated myelofibrosis, other types of MDS, chronic lymphocytic leukaemia (CLL) and sickle cell disease (SCD).
Originele taal-2English
Pagina's (van-tot)21-28
TijdschriftBelgian Journal of Hematology
Nummer van het tijdschrift1
StatusPublished - 1 jun 2013


Duik in de onderzoeksthema's van 'Immunomodulatory drugs: new developments'. Samen vormen ze een unieke vingerafdruk.

Citeer dit